Envveno Medical CORP

enVVeno Medical Corporation has filed an investor presentation on July 14, 2026, providing updates that may be used in discussions with investors and analysts.

enVVeno Medical Corporation announced FDA approval for a pivotal U.S. study of its non-surgical replacement venous valve, the enVVe System, for severe Chronic Venous Insufficiency.

enVVeno Medical Corporation announced it has regained compliance with Nasdaq's minimum bid price requirement and reported approximately $28 million in cash and investments as of December 31, 2025.

enVVeno Medical Corporation has completed a 1-for-35 reverse stock split, significantly reducing outstanding shares and proportionally adjusting equity awards.

enVVeno Medical Corporation's stockholders re-elected directors, approved executive compensation and auditor, but rejected a new equity incentive plan while granting authority for a reverse stock split.

enVVeno Medical Corporation's Board of Directors approved an amendment to its bylaws, reducing the quorum requirement for stockholder meetings to thirty-three and one-third percent of voting power.

enVVeno Medical received a not-approvable letter from the FDA for its VenoValve PMA, leading to an appeal, while also facing a Nasdaq minimum bid price deficiency.

enVVeno Medical Corporation reported increased net losses for the second quarter of 2025, driven by higher operating expenses, while advancing its VenoValve and enVVe medical device programs with positive clinical and preclinical results.

enVVeno Medical Corporation reports a net loss of $4.5 million for Q1 2025, with the VenoValve PMA application under priority review by the FDA.

enVVeno Medical Corporation reported a net loss of $5.6 million for Q3 2024, while also providing updates on the progress of its VenoValve and enVVe medical device programs.

enVVeno Medical Corporation reported a net loss of $9.9 million for the first six months of 2024, while advancing its VenoValve and enVVe programs.

enVVeno Medical Corporation reports positive six-month efficacy data from its SAVVE trial for the VenoValve, with 97% of patients showing clinical improvement, and anticipates filing for FDA approval in Q4 2024.

enVVeno Medical Corporation received a non-approvable letter from the FDA for its VenoValve, prompting a strategic pivot to its next-generation enVVe System, a non-surgical venous valve, with pivotal trials expected to begin in 2026.

enVVeno Medical Corporation amends its Form 10-K to clarify that an FDA decision on its lead product, VenoValve, is expected in the second half of 2025.

enVVeno Medical Corporation reports a net loss of $21.8 million for 2024, emphasizing progress towards FDA approval for its VenoValve product.

enVVeno Medical Corporation's 2023 annual report highlights the full enrollment of the SAVVE trial for VenoValve and accelerated development of enVVe, alongside financial results showing increased R&D spending and a net loss.

Director Francis Duhay sold 140 shares of enVVeno Medical Corp common stock at an average price of $10.305 per share.

enVVeno Medical Corp Director Francis Duhay sold 140 shares of common stock for $11.5224 per share under a pre-arranged 10b5-1 trading plan.

enVVeno Medical Corp's CEO, Robert Andrew Berman, has voluntarily surrendered 200,000 unvested Restricted Stock Units due to unachieved performance milestones.

enVVeno Medical Corp's Chief Technology Officer, Hamed Alavi, has surrendered 50,000 unvested Restricted Stock Units due to unachieved performance milestones.

enVVeno Medical Corp's SVP & Chief Medical Officer, Marc H. Glickman, is scheduled to surrender 100,000 unvested Restricted Stock Units after failing to meet performance milestones.

enVVeno Medical Corp director Francis Duhay was granted 135,883 stock options with a $0.325 exercise price, vesting quarterly in 2026.

enVVeno Medical Corporation is seeking stockholder approval for a reverse stock split to maintain its Nasdaq listing and improve stock marketability.

enVVeno Medical Corporation has filed definitive additional materials for a proxy statement with the SEC.

enVVeno Medical Corporation is awaiting a critical FDA decision on its VenoValve appeal by year-end 2025, while also seeking shareholder approval for a new 2025 Equity Incentive Plan and director elections.

enVVeno Medical Corporation is seeking shareholder approval for the election of directors, executive compensation, and the ratification of their accounting firm at their upcoming annual meeting.

Northstrive Fund II LP and Braeden Lichti, holding a 5.05% stake, have filed a Schedule 13D urging enVVeno Medical Corp to halt clinical operations and explore strategic alternatives including liquidation or merger.

Northstrive Fund II LP and Braeden Lichti, holding a 5.05% stake, demand enVVeno Medical Corp halt clinical operations and initiate a strategic review for capital return or merger.

Kingdon Capital Management, L.L.C. and affiliated entities have reported beneficial ownership of 5.5% of enVVeno Medical Corporation's common stock as of March 31, 2026.

Northstrive Fund II LP and Braeden Lichti have disclosed beneficial ownership of enVVeno Medical Corp common stock, with Lichti holding a 5.05% stake.

Braeden Lichti and Northstrive Fund II LP have disclosed beneficial ownership of 5.05% of enVVeno Medical Corporation's common stock.

Thomas A. Satterfield, Jr. has disclosed a 9.0% beneficial ownership stake in enVVeno Medical Corporation, totaling 1,822,500 shares.

Nantahala Capital Management and its managing members reported a 3.46% beneficial ownership stake in enVVeno Medical Corporation as of September 30, 2025.

Kingdon Capital Management and related entities have reported a 7.1% beneficial ownership stake in enVVeno Medical Corporation's common stock.